Hesitancy to Receive the Second COVID-19 Vaccine Booster Dose among Older Adults in Hong Kong: A Random Telephone Survey

Author:

Chan Paul Shing-fong1ORCID,Lee Marco Lok-tin1,Fang Yuan2ORCID,Yu Fuk-yuen1ORCID,Ye Danhua1,Chen Siyu1ORCID,Kawuki Joseph1ORCID,Liang Xue1,Wang Zixin1ORCID

Affiliation:

1. Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China

2. Department of Health and Physical Education, The Education University of Hong Kong, Hong Kong, China

Abstract

A second COVID-19 vaccine booster dose is effective and safe for older adults. This study investigated hesitancy to take up a second COVID-19 vaccine booster dose and its determinants among older adults in Hong Kong. Participants were Chinese-speaking community-dwelling adults aged 65 years or above. Telephone numbers were randomly selected from up-to-date telephone directories. A total of 370 participants completed the telephone survey. Logistic regression models were fitted for data analysis. Among the participants, half (52.4%) were hesitant to receive the second COVID-19 vaccine booster dose. After adjustment for significant background characteristics, perceived benefits (AOR: 0.50, 95%CI: 0.42, 0.60), cues to action (AOR: 0.39, 95%CI: 0.30, 0.52), and perceived self-efficacy (AOR: 0.37, 95%CI: 0.21, 0.66) of receiving the second booster dose were associated with lower vaccine hesitancy. Perceived barriers (AOR: 1.23, 95%CI: 1.12, 1.34) and vaccine fatigue (tired of receiving repeated COVID-19 vaccination) (AOR: 1.90, 95%CI: 1.52, 2.38) were associated with higher vaccine hesitancy. Level of hesitancy to receive the second booster dose was high among older adults in Hong Kong. Health authorities should address vaccine fatigue and modify perceptions related to the second booster dose.

Funder

Health and Medical Research Fund, Food and Health Bureau, Hong Kong Special Administrative Region

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference49 articles.

1. World Health Organization (2023, January 19). WHO Coronavirus COVID-19 Dashboard. Available online: https://covid19.who.int.

2. Age-Related Morbidity and Mortality among Patients with COVID-19;Kang;Infect. Chemother.,2020

3. Government of Hong Kong SAR (2022, December 19). Latest Situation of Novel Coronavirus Infection in Hong Kong, Available online: https://www.chp.gov.hk/files/pdf/local_situation_covid19_tc.pdf.

4. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study;Bernal;BMJ-Br. Med. J.,2021

5. Effec-tiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: A test-negative, case-control study;Hyams;Lancet Infect Dis.,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3